Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

• Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes
• New data and real-world findings further emphasize pediatric safety, glycemic control and treatment satisfaction
• Exploratory analysis of inhaled insulin used with AID systems provides insight on the impact of total daily dose algorithms
• Data from randomized cross-over trial supports safety and efficacy of inhaled insulin as an alternative to RAA in gestational diabetes

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced new clinical and real‑world data related to Afrezza (insulin human) Inhalation Powder and FUROSCIX (furosemide injection) that will be presented at the American Diabetes Association’s (ADA) 2026 Scientific Sessions, taking place June 5-8, 2026, in New Orleans, Louisiana.

“As we continue to advance care for people living with diabetes, and on the heels of the recent approval of Afrezza in children and adolescents aged 6 and older, the data presented at this year’s ADA meeting further reinforce its established safety and efficacy, while also highlighting benefits that extend beyond glycemic control and into patients’ daily lives,” said Dr. Kevin Kaiserman, Senior Vice President and Therapeutic Area Head-Diabetes for MannKind Corporation. “We are committed to expanding meaningful treatment options that can help people better manage their diabetes in a way that works for them, and the growing body of evidence for Afrezza supports a more individualized and patient-centered approach to care.”

Key presentations:

Participants Achieving HbA1c <8% in Youth Report Greater Treatment Satisfaction with Inhaled Technosphere Insulin vs. Rapid‑Acting Analogs
A post hoc analysis from the INHALE-1 study assessed treatment satisfaction among pediatric participants achieving HbA1c <8% at 26 weeks. Those treated with inhaled insulin reported statistically greater improvements in treatment satisfaction compared to RAA across both teens and parents, while achieving similar overall glycemic outcomes.

Efficacy and Safety of Inhaled Technosphere Insulin (TI) vs. Rapid-Acting Analog in Youth with HbA1c ≤9.5%: Subgroup Analysis from INHALE-1
A subgroup analysis from the INHALE-1 study evaluated efficacy and safety of inhaled insulin compared to rapid‑acting insulin analogs (RAA) in children and adolescents with diabetes with baseline HbA1c ≤9.5%. After 26 weeks, inhaled insulin achieved non-inferior mean HbA1c compared with RAA. Time in range (TIR) was comparable between treatment groups, and rates of adverse events were similar compared to adult data.

Schreibe Deinen Kommentar